A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.
暂无分享,去创建一个
Felipe García | A. León | J. Mallolas | M. Laguno | L. Leal | J. Pich | C. Manzardo | J. Rojas | B. Torres | J. Gatell | A. González-Cordón | C. Lucero | J. Arnaiz | A. Inciarte | M. Martínez-Rebollar | M. Martinez-Rebollar
[1] Felipe García,et al. A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. , 2016, The Journal of antimicrobial chemotherapy.
[2] A. McNulty,et al. Single-Tablet Emtricitabine-Rilpivirine-Tenofovir as HIV Postexposure Prophylaxis in Men Who Have Sex With Men. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] N. Ford,et al. The Strategic Use of Antiretrovirals to Prevent HIV Infection: A Converging Agenda. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] N. Ford,et al. Formulating the Future Research Agenda for Postexposure Prophylaxis for HIV: Methodological Challenges and Potential Approaches. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[5] N. Ford,et al. Adherence to HIV postexposure prophylaxis: a systematic review and meta-analysis , 2014, AIDS.
[6] K. Mayer,et al. Practical guidance for nonoccupational postexposure prophylaxis to prevent HIV infection: an editorial review. , 2014, AIDS.
[7] I. Bogoch,et al. Patient attrition between the emergency department and clinic among individuals presenting for HIV nonoccupational postexposure prophylaxis. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] N. Ford,et al. Systematic review and meta‐analysis: Patient and programme impact of fixed‐dose combination antiretroviral therapy , 2014, Tropical medicine & international health : TM & IH.
[9] David K. Henderson,et al. Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis , 2013, Infection Control & Hospital Epidemiology.
[10] C. Reback,et al. High-Risk Sexual Behavior Is Associated with Postexposure Prophylaxis Nonadherence among Men Who Have Sex with Men Enrolled in a Combination Prevention Intervention , 2013, Journal of sexually transmitted diseases.
[11] John P. Moore,et al. Pharmacokinetics and efficacy of a vaginally administered maraviroc gel in rhesus macaques. , 2013, The Journal of antimicrobial chemotherapy.
[12] M. Mimiaga,et al. Raltegravir, Tenofovir DF, and Emtricitabine for Postexposure Prophylaxis to Prevent the Sexual Transmission of HIV: Safety, Tolerability, and Adherence , 2012, Journal of acquired immune deficiency syndromes.
[13] N. Ford,et al. Adherence to HIV post-exposure prophylaxis in victims of sexual assault: a systematic review and meta-analysis , 2012, Sexually Transmitted Infections.
[14] B. Clotet,et al. Post-Exposure Prophylaxis for HIV Infection: A Clinical Trial Comparing Lopinavir/Ritonavir versus Atazanavir Each with Zidovudine/Lamivudine , 2012, Antiviral therapy.
[15] N. Beeching,et al. HIV post-exposure prophylaxis programmes in the developed and developing world: can we learn from each other? , 2011, International journal of STD & AIDS.
[16] Till Bärnighausen,et al. Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. , 2011, The Lancet. Infectious diseases.
[17] Myron S. Cohen,et al. Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. , 2011, The Journal of infectious diseases.
[18] M. Cavassini,et al. Nonoccupational HIV post‐exposure prophylaxis: a 10‐year retrospective analysis , 2010, HIV medicine.
[19] B. Christian,et al. Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation , 2010, AIDS.
[20] B. Damle,et al. Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women , 2009, Journal of acquired immune deficiency syndromes.
[21] M. Mimiaga,et al. Tenofovir DF Plus Lamivudine or Emtricitabine for Nonoccupational Postexposure Prophylaxis (NPEP) in a Boston Community Health Center , 2008, Journal of acquired immune deficiency syndromes.
[22] J. Delfraissy,et al. Post‐exposure prophylaxis with a maraviroc‐containing regimen after occupational exposure to a multi‐resistant HIV‐infected source person , 2008, Journal of medical virology.
[23] Dongwen Wang,et al. Assessment of Adverse Events Associated With Antiretroviral Regimens for Postexposure Prophylaxis for Occupational and Nonoccupational Exposures to Prevent Transmission of Human Immunodeficiency Virus , 2007, Infection Control & Hospital Epidemiology.
[24] C. Duncombe,et al. Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children adolescents and adults. Recommendations for a public health approach. , 2006 .
[25] J. Kahn,et al. Seroconversion following nonoccupational postexposure prophylaxis against HIV. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[26] L. Grohskopf,et al. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. , 2005, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[27] B. Christian,et al. Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] J. Casabona,et al. Recomendaciones para la profilaxis postexposición no ocupacional al VIH , 2002 .
[29] J. Casado,et al. Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients: the GEEMA Study , 2002, AIDS.
[30] C. Rabaud,et al. Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[31] I. Escobar,et al. Study of the Validity of a Questionnaire to Assess the Adherence to Therapy in Patients Infected by HIV , 2001, HIV clinical trials.
[32] E. Ricci,et al. Haart Tolerability: Post-Exposure Prophylaxis in Healthcare Workers versus Treatment in HIV-Infected Patients , 1999, Antiviral therapy.
[33] R. Paredes,et al. Monitoring adherence to HIV therapy. , 1999, Archives of internal medicine.
[34] J. Lifson,et al. Effectiveness of Postinoculation (R)-9-(2-Phosphonylmethoxypropyl)Adenine Treatment for Prevention of Persistent Simian Immunodeficiency Virus SIVmne Infection Depends Critically on Timing of Initiation and Duration of Treatment , 1998, Journal of Virology.
[35] D. Cardo,et al. Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV-infected blood--France, United Kingdom, and United States, January 1988-August 1994. , 1995, MMWR. Morbidity and mortality weekly report.
[36] R. Gelber,et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. , 1994, The New England journal of medicine.